SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 265 filers reported holding SAGE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 2.21 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $1,937,828 | -20.7% | 103,406 | -8.3% | 0.00% | 0.0% |
Q4 2023 | $2,442,599 | +4.2% | 112,718 | -1.1% | 0.00% | 0.0% |
Q3 2023 | $2,344,536 | -46.3% | 113,923 | +22.8% | 0.00% | -50.0% |
Q2 2023 | $4,362,845 | +8.0% | 92,787 | -3.6% | 0.00% | 0.0% |
Q1 2023 | $4,038,020 | +4.6% | 96,235 | -5.0% | 0.00% | 0.0% |
Q4 2022 | $3,861,636 | +1.5% | 101,249 | +4.2% | 0.00% | 0.0% |
Q3 2022 | $3,806,000 | +21.4% | 97,207 | +0.2% | 0.00% | +33.3% |
Q2 2022 | $3,134,000 | +1.5% | 97,016 | +4.0% | 0.00% | 0.0% |
Q1 2022 | $3,087,000 | -10.3% | 93,308 | +15.3% | 0.00% | +50.0% |
Q4 2021 | $3,443,000 | +6.5% | 80,947 | +11.0% | 0.00% | 0.0% |
Q3 2021 | $3,232,000 | -20.4% | 72,942 | +2.0% | 0.00% | 0.0% |
Q2 2021 | $4,061,000 | +3.1% | 71,486 | +35.8% | 0.00% | 0.0% |
Q1 2021 | $3,939,000 | -29.9% | 52,631 | -19.0% | 0.00% | -33.3% |
Q4 2020 | $5,618,000 | +30.9% | 64,946 | -7.5% | 0.00% | 0.0% |
Q3 2020 | $4,293,000 | -10.3% | 70,249 | -39.0% | 0.00% | 0.0% |
Q2 2020 | $4,786,000 | +91.1% | 115,108 | +31.9% | 0.00% | +50.0% |
Q1 2020 | $2,505,000 | -44.7% | 87,251 | +39.1% | 0.00% | -33.3% |
Q4 2019 | $4,528,000 | -1.3% | 62,734 | +91.9% | 0.00% | -25.0% |
Q3 2019 | $4,587,000 | -42.7% | 32,692 | -25.3% | 0.00% | -42.9% |
Q2 2019 | $8,009,000 | -54.6% | 43,745 | -60.5% | 0.01% | -56.2% |
Q1 2019 | $17,635,000 | +535.7% | 110,873 | +282.9% | 0.02% | +433.3% |
Q4 2018 | $2,774,000 | -40.0% | 28,958 | -11.5% | 0.00% | -25.0% |
Q3 2018 | $4,620,000 | -14.8% | 32,709 | -5.5% | 0.00% | -20.0% |
Q2 2018 | $5,420,000 | -35.8% | 34,628 | -33.9% | 0.01% | -37.5% |
Q1 2018 | $8,440,000 | +22.3% | 52,400 | +25.0% | 0.01% | +33.3% |
Q4 2017 | $6,902,000 | +42.1% | 41,907 | -46.3% | 0.01% | +20.0% |
Q3 2017 | $4,857,000 | -3.7% | 77,977 | +23.1% | 0.01% | 0.0% |
Q2 2017 | $5,044,000 | -18.9% | 63,347 | -27.6% | 0.01% | -16.7% |
Q1 2017 | $6,217,000 | +0.9% | 87,489 | -27.5% | 0.01% | 0.0% |
Q4 2016 | $6,162,000 | +105.7% | 120,685 | +85.5% | 0.01% | +100.0% |
Q3 2016 | $2,996,000 | +186.2% | 65,052 | +87.0% | 0.00% | +200.0% |
Q2 2016 | $1,047,000 | -10.3% | 34,783 | -4.4% | 0.00% | 0.0% |
Q1 2016 | $1,167,000 | +200.8% | 36,401 | +446.2% | 0.00% | – |
Q4 2015 | $388,000 | -41.7% | 6,665 | -57.7% | 0.00% | -100.0% |
Q3 2015 | $666,000 | -78.6% | 15,762 | -63.0% | 0.00% | -66.7% |
Q2 2015 | $3,109,000 | +197.8% | 42,594 | +104.9% | 0.00% | +200.0% |
Q1 2015 | $1,044,000 | +172.6% | 20,784 | +98.2% | 0.00% | – |
Q4 2014 | $383,000 | – | 10,485 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
RA Capital Management | 350,933 | $49,569,000 | 2.65% |
Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |